Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile

European urology oncology - Tập 4 - Trang 297-300 - 2021
Jean Hoffman-Censits1,2, Woonyoung Choi3, Sumanta Pal4, Edouard Trabulsi5, William Kevin Kelly6, Noah M. Hahn1,2, David McConkey7, Eva Comperat8,9, Andres Matoso10, Oliver Cussenot8,9, Geraldine Cancel-Tassin8,9, Megan Hoi Yan Fong7, Jeffrey Ross11, Russell Madison11, Siraj Ali11
1Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
2Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
3The James Buchanan Brady Urological Institute, Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
4Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, CA, USA
5Department of Urology, The Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA
6Department of Medical Oncology, The Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA, USA
7Johns Hopkins Greenberg Bladder Cancer Institute, Baltimore, MD, USA
8CeRePP, Paris, France
9Sorbonne Universite, GRC n°5, AP-HP, Hopital Tenon, Paris, France
10Department of Pathology, Johns Hopkins Hospital, Baltimore, MD, USA
11Foundation Medicine, Inc, Cambridge, MA, USA

Tài liệu tham khảo

Cumberbatch, 2018, Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018, Eur Urol, 74, 784, 10.1016/j.eururo.2018.09.001 Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Kouba, 2017, Understanding the genetic landscape of small cell carcinoma of the urinary bladder and implications for diagnosis, prognosis, and treatment: a review, JAMA Oncol, 3, 1570, 10.1001/jamaoncol.2016.7013 Robertson, 2017, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 171, 10.1016/j.cell.2017.09.007 Siefker-Radtke, 2009, Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer, J Clin Oncol, 27, 2592, 10.1200/JCO.2008.19.0256 Chang, 2018, Small cell carcinomas of the bladder and lung are characterized by a convergent but distinct pathogenesis, Clin Cancer Res, 24, 1965, 10.1158/1078-0432.CCR-17-2655 Priemer, 2018, Small-cell carcinomas of the urinary bladder and prostate: TERT promoter mutation status differentiates sites of malignancy and provides evidence of common clonality between small-cell carcinoma of the urinary bladder and urothelial carcinoma, Eur Urol Focus, 4, 880, 10.1016/j.euf.2017.03.007 Flaig, 2018, NCCN guidelines insights: bladder cancer, version 5.2018, J Natl Compr Canc Netw, 16, 1041, 10.6004/jnccn.2018.0072 Wilde, 2017, Response to pembrolizumab in a patient with chemotherapy refractory bladder cancer with small cell variant histology: a case report and review of the literature, Clin Genitourin Cancer, 15, e521, 10.1016/j.clgc.2016.12.012
Thông tin
Thông tin xuất bản

European urology oncology

Tập 4

297-300

Thông tin tác giả